Stub

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 21:23, 27 June 2021 by Jwarner (talk | contribs) (→‎A-ICE)
Jump to navigation Jump to search

Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the Ontology.


3M

back to top

3M: Mitomycin, Mitoxantrone, Methotrexate

Regimen

Chemotherapy

7+3i & Clofarabine

back to top

7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine

Regimen

Chemotherapy

7+3i & Lenalidomide

back to top

7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide

Regimen

Chemotherapy

Targeted therapy

7+4i

back to top

7+4i: 7 days of cytarabine, 4 days of idarubicin

Regimen

Chemotherapy

7+5d

back to top

7+5d: 7 days of cytarabine, 5 days of daunorubicin

Regimen

Chemotherapy

Abiraterone & Enzalutamide

back to top

Regimen

Endocrine therapy

ACP

back to top

ACP: Atezolizumab, Carboplatin, Paclitaxel

Regimen

Immunotherapy

Chemotherapy

Afatinib & Vinorelbine

back to top

Regimen

Chemotherapy

Targeted therapy

A-ICE

back to top

A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide

Regimen

Targeted therapy

Chemotherapy

AME

back to top

AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide

Regimen

Chemotherapy

Amonafide & Cytarabine

back to top

Regimen

Chemotherapy

Amsacrine & IDAC

back to top

Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)

Regimen

Chemotherapy

Bortezomib & Bevacizumab

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
White et al. 2012 (AMBER) 2007-2009 Randomized Phase II (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.74, 95% CI 0.43-1.28)

Targeted therapy

Bortezomib & Siltuximab

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Orlowski et al. 2015 (CR012784) 2006-2009 Randomized Phase II (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.87, 95% CI 0.65-1.16)

Targeted therapy

BTH (Taxotere)

back to top

BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)

Regimen

Chemotherapy

Targeted therapy

BTOC

back to top

BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide

Regimen

Chemotherapy

CAD

back to top

CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)

Regimen

Chemotherapy

Capecitabine & Cisplatin (CX) & Bevacizumab

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Cisplatin (CX) & Ramucirumab

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Ruxolitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sorafenib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sunitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Vinflunine

back to top

Regimen

Chemotherapy

Capecitabine & Vinorelbine

back to top

NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)

Regimen

Chemotherapy

Capecitabine, Cisplatin, Cetuximab, RT

back to top

Regimen

Chemotherapy

Targeted therapy

Radiotherapy

Capecitabine, Erlotinib, RT

back to top

Regimen

Chemotherapy

Radiotherapy

CarboMIP

back to top

CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

Carboplatin & Epirubicin

back to top

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Bexarotene

back to top

CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Cediranib

back to top

CP & Cediranib: Carboplatin, Paclitaxel, Cediranib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Cetuximab

back to top

CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Erlotinib

back to top

CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & PLD

back to top

TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Sorafenib

back to top

CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Topotecan

back to top

TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Trebananib

back to top

TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Vergote et al. 2019 (TRINOVA-3) 2012-2014 Phase III (E-esc) TC Did not meet primary endpoint of PFS
(HR 0.93, 95% CI 0.79-1.09)

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Veliparib

back to top

CP & Veliparib: Carboplatin, Paclitaxel, Veliparib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Topotecan

back to top

Regimen

Chemotherapy

CBM

back to top

CBM: Capecitabine, Bevacizumab, Mitomycin

Regimen

Chemotherapy

Targeted therapy

CCG

back to top

CCG: Cisplatin, Carboplatin, Gemcitabine

Regimen

Chemotherapy

Carboplatin & Etoposide (CE) & Ipilimumab

back to top

CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab

Regimen

Chemotherapy

Immunotherapy

Carboplatin & Etoposide (CE) & Thalidomide

back to top

CE & Thalidomide: Carboplatin, Etoposide, Thalidomide

Regimen

Chemotherapy

Targeted therapy

CIB

back to top

CIB: Cisplatin, Ifosfamide, Bleomycin

Regimen

Chemotherapy

Cisplatin & Methotrexate

back to top

Regimen

Chemotherapy

Cisplatin & Treosulfan

back to top

Regimen

Chemotherapy

Cisplatin & Vincristine

back to top

Regimen

Chemotherapy

Cisplatin, Avelumab, RT

back to top

Regimen

Chemotherapy

Immunotherapy

Radiotherapy

Cisplatin, Pemetrexed, RT

back to top

Regimen

Chemotherapy

Radiotherapy

CODE

back to top

CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide

Regimen

Chemotherapy

CYVADIC

back to top

CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)

Regimen

Chemotherapy

DBCT

back to top

DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Docetaxel & Bavituximab

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Ganetespib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Gefitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Lapatinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Pertuzumab

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Selumetinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Sunitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & ziv-Aflibercept

back to top

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Etoposide

back to top

Regimen

Chemotherapy

Doxorubicin & Paclitaxel

back to top

Regimen

Chemotherapy

Doxorubicin & Sorafenib

back to top

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Streptozocin

back to top

Regimen

Chemotherapy

Doxorubicin & Vinorelbine

back to top

Regimen

Chemotherapy

EAP

back to top

EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)

Regimen

Chemotherapy

ECVBP

back to top

ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone

Regimen

Chemotherapy

ELF

back to top

ELF: Etoposide, Leucovorin, 5-FU

Regimen

Chemotherapy

Encorafenib monotherapy

back to top

Regimen

Targeted therapy

EP & Ipilimumab

back to top

EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab

Regimen

Chemotherapy

Immunotherapy

EP, Tamoxifen, RT

back to top

EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy

Regimen

Chemotherapy

Endocrine therapy

Radiotherapy

Erlotinib & Figitumumab

back to top

Regimen

Targeted therapy

Erlotinib & Onartuzumab

back to top

Regimen

Targeted therapy

Erlotinib & Sunitinib

back to top

Regimen

Targeted therapy

Erlotinib & Tivantinib

back to top

Regimen

Targeted therapy

Everolimus & Vinorelbine

back to top

Regimen

Chemotherapy

Targeted therapy

E-GEMOX

back to top

E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin

Regimen

Targeted therapy

Chemotherapy

FAP

back to top

FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)

Regimen

Chemotherapy

Immunotherapy

FEC & HP

back to top

FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab

Regimen

Chemotherapy

Targeted therapy

FLA

back to top

FLA: FLudarabine & Ara-C (Cytarabine)

Regimen

Chemotherapy

FLAI

back to top

FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)

Regimen

Chemotherapy

FOLF-CB

back to top

FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab

Regimen

Chemotherapy

Targeted therapy

FULV & Trimetrexate

back to top

FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate

Regimen

Chemotherapy

Cisplatin & Gemcitabine (GC) & Veliparib

back to top

GC & Veliparib: Gemcitabine, Cisplatin, Veliparib

Regimen

Chemotherapy

Targeted therapy

GVP

back to top

GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)

Regimen

Chemotherapy

Ibrutinib & Ublituximab

back to top

Regimen

Targeted therapy

Ixabepilone & Bevacizumab

back to top

Regimen

Chemotherapy

Targeted therapy

ME

back to top

ME: Mitoxantrone & Etoposide

Regimen

Chemotherapy

MEV

back to top

MEV: Mitomycin, Etoposide, Vindesine

Regimen

Chemotherapy

MFL

back to top

MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)

Regimen

Chemotherapy

MFT

back to top

MFL: Methotrexate, 5-FU, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Mitoxantrone & Hydrocortisone

back to top

Regimen

Chemotherapy

Endocrine therapy

MMF

back to top

MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU

Regimen

Chemotherapy

MPP

back to top

MPP: Melphalan, Prednisone, Procarbazine

Regimen

Chemotherapy

MTP

back to top

MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel

Regimen

Chemotherapy

Targeted therapy

MVC

back to top

MVC: Mitomycin, Vindesine, Carboplatin

Regimen

Chemotherapy

NIP

back to top

NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

PD & Pembrolizumab

back to top

PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Mateos et al. 2019 (KEYNOTE-183) 2016-2017 Phase III (E-esc) PD Seems to have inferior PFS
(HR 1.53, 95% CI 1.05-2.22)

Targeted therapy

Chemotherapy

Immunotherapy

PEI

back to top

PEI: Platinol (Cisplatin), Etoposide, Ifosfamide

Regimen

Chemotherapy

PELF

back to top

PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU

Regimen

Chemotherapy

PGT

back to top

PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)

Regimen

Chemotherapy

PGV

back to top

PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine

Regimen

Chemotherapy

Pemetrexed & Cetuximab

back to top

Regimen

Chemotherapy

Targeted therapy

Pemetrexed & Vandetanib

back to top

Regimen

Chemotherapy

Targeted therapy

Pixantrone & Rituximab

back to top

Regimen

Chemotherapy

Targeted therapy

PLD & Trebananib

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Marth et al. 2016 (TRINOVA-2) 2011-2013 Phase III (E-esc) PLD Did not meet primary endpoint of PFS
(HR 0.92, 95% CI 0.68-1.24)

Chemotherapy

Targeted therapy

PVI

back to top

PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

R-BEACOPP

R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen

Targeted therapy

Chemotherapy

R-MegaCHOEP

back to top

R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone

Targeted therapy

Chemotherapy

TCG

back to top

TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine

Regimen

Chemotherapy

TCHL (Taxotere)

back to top

TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib

Regimen

Chemotherapy

Targeted therapy

TCL (Taxotere)

back to top

TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib

Regimen

Chemotherapy

Targeted therapy

TEC

back to top

TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin

Regimen

Chemotherapy

TG+Bev

back to top

TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab

Regimen

Chemotherapy

Targeted therapy

TH (Taxol) & Everolimus

back to top

TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus

Regimen

Chemotherapy

Targeted therapy

TL (Taxotere)

back to top

TL: Taxotere (Docetaxel) & Lapatinib

Regimen

Chemotherapy

Targeted therapy

TPCV

back to top

TPCV: Thioguanine, Procarbazine, CCNU, Vincristine

Regimen

Chemotherapy

TX+Bev

back to top

TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab

Regimen

Chemotherapy

Targeted therapy

VADx

back to top

VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone

Regimen

Chemotherapy

VAPEC-B

back to top

VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin

Regimen

Chemotherapy

VBM (Vinblastine)

back to top

VBM: Vinblastine, Bleomycin, Methotrexate

Regimen

Chemotherapy

VCE

back to top

VCE: Vincristine, Carboplatin, Etoposide

Regimen

Chemotherapy

Vinorelbine & Hydrocortisone

back to top

Regimen

Chemotherapy

Endocrine therapy

VNC

back to top

VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide

Regimen

Chemotherapy

VPV

back to top

VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)

Regimen

Chemotherapy

VTDC

back to top

VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide

Regimen

Targeted therapy

Chemotherapy